Dose-finding Study in Platinum-Resistant Ovarian Cancer

Phase I Inclusion Criteria: * Female, 18 years of age as of signing the informed consent form, capable of giving/complying with written informed consent * Histologically or cytologically confirmed serous ovarian cancer (includes primary peritoneal and Fallopian tube) * Negative serum pregnancy test in women of childbearing potential within 14 days of first dose of treatment, agree to use effective contraception during/after (6 months post dose of paclitaxel or 30 days post dose GSK2110183 whichever is longer) * Performance Status score of 0-2 according to the ECOG scale. * Able to swallow and retain oral medication * Subjects diagnosed previously with Type 2 diabetes must have been diagnosed ≥ 6 months prior to enrollment * Prior treatment-related toxicities (except for alopecia) must be ≤ Grade 1 according to NCI-CTCAE (Version 4.0 \[NCI, 2009\]) at the time of treatment allocation OR ≤ Grade 2 and stable for 4 weeks or longer at the time of screening evaluation. Exception: Subjects with peripheral neuropathy \>/= Grade 2 will NOT be eligible * Adequate organ system function Phase II Inclusion Criteria: Cohort A * Phase I criteria * Documented complete or partial response by RECIST to at least 1 prior platinum-based therapy * Progression defined by either (1) RECIST v1.1 criteria or (2) GCIG CA 125 criteria associated with symptoms necessitating treatment between 1 and 6 months of prior platinum-based therapy either in adjuvant or metastatic setting * Subjects allowed to have a maximum of one non-platinum-based therapy between the onset of platinum resistance * Must have radiologically measurable disease i.e. presenting with at least one measurable lesion per RECIST 1.1 Cohort B * Phase I criteria * Documented complete or partial response by RECIST to at least 1 prior platinum-based therapy * Progression defined by either (1) RECIST v1.1 criteria or (2) GCIG CA 125 criteria associated with symptoms necessitating treatment while being treated with a regimen containing carboplatin and paclitaxel (or within 4 weeks of completing treatment) * Subjects will be required to start on treatment within 8 weeks after the last infusion of chemotherapy and may not have had any other anti-cancer therapy in the intervening time * Must have radiologically measurable disease i.e. presenting with at least one measurable lesion per RECIST 1.1 * Additional restrictions on number of prior therapies may be added to eligibility criteria based on emerging data Exclusion Criteria: * History of another malignancy (some exceptions may apply) * Serious and/or unstable pre-existing medical or psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures * Current use of prohibited medication during treatment. * Chemotherapy, immunotherapy, or other anti-cancer therapy within 14 days prior to the first dose study drug * Radiotherapy prior to initiation of therapy (some exceptions may apply) * Contraindications (identified by the investigator) to the doses of carboplatin and/or paclitaxel * History of reduction in standard of care paclitaxel dose for peripheral neuropathy * No known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar or related to GSK2110183 * No known delayed hypersensitivity reaction or idiosyncratic reaction to drugs similar to carboplatin or paclitaxel (some exceptions may apply) * Prior use of a drug that targets AKT including perifosine * History of Type 1 diabetes * Gastrointestinal disease or other condition that could affect absorption or predispose subject to gastrointestinal ulceration * Mucosal or internal bleeding * Major surgery within the last four weeks * Infection requiring parenteral or oral anti-infective treatment * Severe or uncontrolled systemic diseases * Brain metastases and/or leptomeningeal disease * QTcF interval ≥ 470 msecs * Bundle branch block, pacemaker or clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block * History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty,stenting or bypass grafting within six months of Screening * Class II, III or IV heart failure as defined by the NYHA functional classification system * Pregnant or lactating female * Malignancies related to HIV or solid organ transplant; history of known HIV, history of know HBV surface antigen positivity (subjects with documented laboratory evidence of HBV clearance may be enrolled) or positive HCV antibody